TY - JOUR
T1 - Airway smooth muscle and long-Term clinical efficacy following bronchial thermoplasty in severe asthma
AU - Wijsman, Pieta C.
AU - Goorsenberg, Annika W. M.
AU - D'Hooghe, Julia N. S.
AU - ten Hacken, Nick H. T.
AU - J t H Roelofs, Joris
AU - Mauad, Thais
AU - Weersink, Els J. M.
AU - Shah, Pallav
AU - Annema, Jouke T.
AU - Bonta, Peter I.
N1 - Publisher Copyright: © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2024/2/12
Y1 - 2024/2/12
N2 - The mechanism of action of bronchial thermoplasty (BT) treatment for patients with severe asthma is incompletely understood. This study investigated the 2.5-year impact of BT on airway smooth muscle (ASM) mass and clinical parameters by paired data analysis in 22 patients. Our findings demonstrate the persistence of ASM mass reduction of >50% after 2.5 years. Furthermore, sustained improvement in asthma control, quality of life and exacerbation rates was found, which is in line with previous reports. An association was found between the remaining ASM and both the exacerbation rate (r=0.61, p=0.04 for desmin, r=0.85, p<0.01 for alpha smooth muscle actin (SMA)) and post-bronchodilator forced expiratory volume in 1 s predicted percentage (r=-0.69, p=0.03 for desmin, r=-0.58, p=0.08 for alpha SMA). This study provides new insight into the long-Term impact of BT.
AB - The mechanism of action of bronchial thermoplasty (BT) treatment for patients with severe asthma is incompletely understood. This study investigated the 2.5-year impact of BT on airway smooth muscle (ASM) mass and clinical parameters by paired data analysis in 22 patients. Our findings demonstrate the persistence of ASM mass reduction of >50% after 2.5 years. Furthermore, sustained improvement in asthma control, quality of life and exacerbation rates was found, which is in line with previous reports. An association was found between the remaining ASM and both the exacerbation rate (r=0.61, p=0.04 for desmin, r=0.85, p<0.01 for alpha smooth muscle actin (SMA)) and post-bronchodilator forced expiratory volume in 1 s predicted percentage (r=-0.69, p=0.03 for desmin, r=-0.58, p=0.08 for alpha SMA). This study provides new insight into the long-Term impact of BT.
KW - Asthma
UR - http://www.scopus.com/inward/record.url?scp=85185481911&partnerID=8YFLogxK
U2 - 10.1136/thorax-2023-220967
DO - 10.1136/thorax-2023-220967
M3 - Article
C2 - 38346871
SN - 0040-6376
VL - 79
SP - 359
EP - 362
JO - Thorax
JF - Thorax
IS - 4
M1 - 220967
ER -